Teva, Cephalon Gets $72 Million EU Fine for Nuvigil Pay-for-Delay

Teva Pharmaceutical Industries Ltd. and its Cephalon unit were fined 60.5 million euros ($72 million) by the European Union for a pact that delayed sales of a cheaper version of a sleep-disorder drug.

Teva received cash payments and struck beneficial commercial side deals with Cephalon that stopped it from rolling out a generic version of Cephalon’s modafinil medicine, the European Commission said in an emailed statement. Their pay-for-delay pact lasted from 2005 until 2011, when Teva bought Cephalon for $6.2 billion.

Read the full article here.

Source: Bloomberg

Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.